This meeting took place in the past. For a complete list of the meetings for the upcoming/current season, see our meeting list or click on related meetings tab below to check for related meeting(s).
Web Desc
Cancer Immunology and Immunotherapy: Taking a Place in Mainstream Oncology
Organizer(s): Robert D. Schreiber, James P. Allison, Philip D. Greenberg and Glenn Dranoff
Date: March 19 - 23, 2017
Location: Fairmont Chateau Whistler, Whistler, BC, Canada
Sponsored by Astellas Pharma Inc., AstraZeneca, BioLegend, Inc., Bristol-Myers Squibb Company, Cell Research, Cell Signaling Technology, Inc., Genentech, Inc., Genmab A/S, ImmunoGen, Inc., Incyte Corporation, Juno Therapeutics, Merck & Co., Inc., Mersana Therapeutics, MorphoSys AG, OncoMed Pharmaceuticals, Inc. ,Pfizer Inc., Regeneron Pharmaceuticals, Inc., Roche, Sangamo Therapeutics, Inc., Takeda Pharmaceutical Company Limited and TESARO, Inc. Part of the Keystone Symposia Global Health Series, supported by the Bill & Melinda Gates Foundation.
Summary of Meeting:
The fields of cancer immunology and immunotherapy continue to make great strides in providing both a comprehensive understanding of the basic mechanisms underlying tumor-immune system interactions and applying this knowledge to the development of effective immune-based cancer therapies. This Keystone Symposia meeting is organized to highlight recent insights into the complex roles of immune components and pathways in controlling or alternatively promoting cancer and to showcase recent uses of cancer vaccines, checkpoint blocking strategies, adoptive cell therapies and cellular engineering approaches, either as mono- or combinatorial therapies, that have resulted in durable, effective and safe therapeutic responses to an increasing number of cancer patients. Part of the meeting will also focus on new, developing technologies that are likely to expand our capacity to monitor the effects of cancer immunotherapy with a precision, refinement and at a level that has not been possible in the past.
Keystone Symposia thanks our Sponsor(s) for generously supporting this meeting:
Astellas Pharma Inc.AstraZenecaBill & Melinda Gates FoundationBioLegend, Inc.Bristol-Myers Squibb CompanyCell ResearchCell Signaling Technology, Inc.Genentech, Inc.Genmab A/SImmunoGen, Inc.Incyte CorporationJuno TherapeuticsMerck & Co., Inc.Mersana TherapeuticsMorphoSys AGOncoMed Pharmaceuticals, Inc.Pfizer Inc.Regeneron Pharmaceuticals, Inc.RocheSangamo Therapeutics, Inc.Takeda Pharmaceutical Company LimitedTESARO, Inc.
We gratefully acknowledge additional support for this conference from:
Adipogen InternationalAmerican Association for Cancer Research (AACR)Cellcion, LLCInSphero Inc.Opsona Therapeutics LtdPersonalis Inc.ProSci Inc.
We gratefully acknowledge additional in-kind support for this conference from those foregoing speaker expense reimbursements:

Novartis Institutes for BioMedical Research
We appreciate the organizations that provide Keystone Symposia with additional support, such as marketing and advertising:
Journal for the Immunotherapy of Cancer (BioMed Central Ltd)
We gratefully acknowledge the generous grant for this conference provided by:

National Cancer Institute (NCI)
Grant No. 1R13CA216951-01
Funding for this conference was made possible (in part) by CA216951-01 from the National Institutes of Heath. The views expressed in written conference materials or publications and by speakers and moderators do not necessarily reflect the official policies of the Department of Health and Human Services; nor does mention of trade names, commercial practices, or organizations imply endorsement by the U.S. Government.
We appreciate the organizations that provide Keystone Symposia with additional support, such as marketing and advertising:

Click here to view more of these organizations
Special thanks to the following for their support of Keystone Symposia initiatives to increase participation at this meeting by scientists from underrepresented backgrounds:

Click here to view more of these organizations

No content found

No content found

No content found

No content found